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Abstract
BACKGROUND: Over the past decades, patient satisfaction has been increasingly recognized as a powerful tool to 
measure the quality of health-care services. 
AIM: This study evaluated the satisfaction of systemic lupus erythematosus (SLE) patients with current clinical 
management in Semey, East Kazakhstan, and explored the factors associated with dissatisfaction.
METHODS: All adult SLE patients registered at health-care facilities of Semey were enrolled in a cross-sectional 
study. 
RESULTS: Out of 67 patients, 66 were females and their mean age was 39 years. Symptoms associated with the 
musculoskeletal system were the most commonly reported (95.5%), followed by fatigue (88.1%) and neurological 
symptoms (53.7%). None of the patients were very satisfied or satisfied with current clinical management and the 
overall rate of patient dissatisfaction was 83.6%. Education (p = 0.04), monthly income (p = 0.01), SLE disease 
activity index score (p = 0.031), therapy with biologic agents (p = 0.029), immunosuppressants (p = 0.01), and 
corticosteroids (p = 0.01) were predictors of patient dissatisfaction in multiple logistic regression analysis.
CONCLUSION: This real-world study is the first effort to understand the experience of SLE patients within the health-
care system of Kazakhstan and the results may facilitate doctor-patient discussions on the initiatives that need to be 
taken to improve the quality of the medical services provided.
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Introduction
At present, patient satisfaction is extensively 
used to evaluate the quality of health-care services, as 
it is considered an important indicator of health-care 
system functioning. Patient satisfaction has multiple 
influences on patient compliance and retention, 
treatment outcomes, and medical malpractice claims [1]. 
In general, patients are likely to be satisfied with the 
quality of services if these are provided in a timely, 
efficient, and patient-oriented manner. The nature of 
disease might also affect satisfaction with the quality 
of care as patients suffering from chronic progressive 
disorders tend to be less satisfied [2].
Systemic lupus erythematosus (SLE) is 
characterized by gradual worsening of general 
symptoms with periodic remissions and relapses under 
treatment. There is no cure for this disease and available 
therapies can only postpone disability and fatality [3]. 
SLE is treated with a variety of drugs, including non-
steroidal anti-inflammatory drugs, corticosteroids 
(CSs), antimalarials, immunosuppressants (ISs), and 
disease-modifying antirheumatic drugs (DMARDs). 
Nowadays, a “treat to target” strategy is applied, 
signifying that remission or low disease activity is a 
primary therapeutic target [4]. 
Being SLE one of the “great masqueraders,” 
it is often diagnosed after multiple visits of the patients 
to health-care facilities with many tests performed [5]. 
Moreover, adherence to treatment and drug compliance 
appear to be poor, as only a quarter of all SLE patients 
take 80% of prescribed medications or more within a 
period of 2 years [6]. Being poor compliance associated 
with worse clinical outcomes, patients are less likely 
to be satisfied with the quality of care. To improve 
treatment adherence, medical professionals try to 
minimize adverse effects while improving treatment 
efficacy and need to balance a range of factors such as 
number of drugs prescribed and dose intervals [7], [8].
A number of international studies reported 
about satisfaction of SLE with the care provided and 
complexity of treatment regimen and the balance 
between treatment efficacy and adverse effects 
were among the most important determinants [9]. 
Meanwhile, according to Jolly and co-authors, 
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greater social support and coping were associated 
with higher satisfaction in SLE patients [10]. 
Such physical factors as tenderness of joints and 
pain on movement, fatigue, anxiety, malar rash, 
and photosensitivity were associated with higher 
dissatisfaction of SLE patients [11]. Notwithstanding 
that patient satisfaction has been increasingly studied 
by Kazakhstani care providers over the past years, no 
data about satisfaction with the quality of care of SLE 
patients exist [12], [13].  Thus, our study evaluated the 
satisfaction of SLE patients in Semey, East Kazakhstan.
Methods and Patients
This was a cross-sectional study, conducted 
from May 2018 to June 2019, which enrolled all adult 
SLE patients registered at the health-care facilities of 
Semey. The Regional Health Authority has established 
a Rheumatology Clinical Registry that collects 
compulsory information on all patients with confirmed 
rheumatologic disorders during the course of routine 
clinical practice. From the electronic database, we 
extracted information on all SLE patients aged 18 
years and older, contacted them by phone, and invited 
them to participate in the study. The only exclusion 
criteria were a psychiatric disease-causing cognitive 
impairment and inability to take part in the study (in 
the investigator’s opinion) and patient’s refusal to take 
part in the study. All 67 invited patients accepted to 
participate.
All patients were interviewed during their 
regular visits to the rheumatologist following them, 
without the presence of any eventual accompanying 
person. Before a patient was interviewed, his/her 
rheumatologist filled in a record form containing 
information related to the SLE status (including time 
course, presence of disability, organ involvement, 
Systemic Lupus International Collaborating Clinics 
American College of Rheumatology (SLICC/ACR) 
index, SLE disease activity index (SLEDAI), and type 
of treatment prescribed). To quantify the damage that 
had occurred since SLE onset, the SLICC/ACR index 
was applied [14], while to assess SLE, the SLEDAI was 
used [15].
All patients were asked to complete a paper 
questionnaire consisting of a demographic part and a 
patient satisfaction part. The demographic questions 
were related to patient’s age, gender, ethnicity, 
education, and personal income (defined on the basis 
of the median salary as of 2017 according to the 
report of the National Committee on Statistics) [16].  To 
describe the degree of satisfaction with current clinical 
management and status monitoring, patients were 
asked to self-evaluate the extent of their satisfaction 
on the basis of a six-point Likert scale (very satisfied, 
satisfied, somewhat satisfied, somewhat dissatisfied, 
dissatisfied, and very dissatisfied) [17]. Subsequently, 
for the purposes of logistic regression analysis, 
we dichotomized the degree of satisfaction using 
the following cutoff points: Satisfied (very satisfied, 
satisfied, or somewhat satisfied) and dissatisfied (very 
dissatisfied, dissatisfied, or somewhat dissatisfied).
Ethical Aspects
Approval of the Ethics Committee of Semey 
Medical University was obtained before the start of the 
study. All SLE patients gave written informed consent 
to participate after receiving detailed information on the 
study aim and procedures. Confidentiality of data was 
ensured.
Statistical analysis
The data analysis comprised three stages 
and was performed using IBM SPSS Statistics 20 
software. Before application of any statistical test, the 
Shapiro–Wilk test was used to define normal data 
distribution. The 95% confidence interval of proportion 
was calculated using Wald method.
At the first stage of data analysis, the 
basic descriptive statistics were conducted on 
sociodemographic and clinical characteristics of SLE 
patients. While continuous variables were evaluated 
with the help of frequencies and means, categorical 
variables were evaluated based on the number and 
percentage of patients in each category. No missing 
data had to be removed from the list of variables, as 
both rheumatologists and SLE patients answered 
all questions. At the second stage of data analysis, 
descriptive tests of various sociodemographic and 
clinical factors associated with patient satisfaction were 
carried out.
At the third stage, we performed multiple 
logistic regression analysis for dichotomous 
outcomes to identify various risk factors associated 
with patient dissatisfaction. For this, we combined 
three grades of dissatisfaction (very dissatisfied, 
dissatisfied, or somewhat dissatisfied) into one 
(dissatisfied). Patient age was dichotomized into 
<40 years and ≥40 years. Education level was 
dichotomized into the higher or secondary vocational 
and secondary or unfinished secondary. Monthly 
income was dichotomized into ≤83,000 Tenge and 
more than 83,000 Tenge (median monthly salary in 
the Republic of Kazakhstan as of 2017). SLICC/ACR 
score was categorized as no damage (score = 0) and 
presence of any damage (score ≥1), while SLEDAI 
score was dichotomized as a score < 4 and equal 
to 4 and higher.
For all data analyses conducted, p < 0.05 were 
considered statistically significant.
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Results
Overall, this study comprised 67 SLE patients, 
of whom 66 (98.5%) were females. Most patients 
(86.6%) were of Kazakh origin, which corresponds 
with ethnic structure of Kazakhstani population [18]. 
The mean age was 39 years (SD ± 12). About half of 
all patients (49.3%) had attained higher or secondary 
vocational education. Most people (79.1%) had a 
monthly income of <83,000 Tenge and the majority 
of patients (82.1%) had been followed-up for 1 year 
or longer. The sociodemographic data of the patient 
population studied are summarized in Table 1.
The most commonly reported symptoms were 
associated with the musculoskeletal system (95.5%) 
followed by fatigue (88.1%). Neurological symptoms 
were the third most frequently reported (53.7%), 
while gastrointestinal symptoms were reported by 
49.3% of patients. Symptoms of depression or anxiety 
were present only in 13.4% of patients and seizures 
were reported by one patient (1.5%) (Table 2). The 
majority of patients (97.0%) were treated with CSs 
while 10.4% received ISs and only one patient (1.5%) 
was on DMARDs therapy. All patients on CS therapy 
(methylprednisolone) and ISs (mycophenolate mofetil) 
received the drugs for free according to the Provision 
Table 1: Sociodemographic characteristics of the study 
participants (n = 67)
Characteristic n %
Gender
Female 66 98.5
Male 1 1.5
Ethnic origin
Kazakhs 58 86.6
Russians 9 13.4
Age, mean ± standard deviation
39 ± 12 years
Education
Unfinished secondary 9 13.4
Secondary 25 37.3
Secondary vocational 18 26.9%
Higher 15 22.4
Monthly incomea
≤83,000 Tenge* 53 79.1
More than 83,000 Tenge * 14 20.9
Duration of follow-up
<1 year 12 17.9
More than 1 year 55 82.1
Age at presentation of first clinical symptoms, mean ± standard deviation
30 ± 11 years
a83,000 Tenge is equivalent to 254.6 USD as of 2017.
of a guaranteed amount of free medical care in 
Kazakhstan [19].
None of the patients were satisfied or very 
satisfied with their current clinical management and 
status monitoring. Only 11 patients (16.4%) were 
somewhat satisfied with the quality of care and the 
rest were dissatisfied to a certain extent. Level of 
education and monthly income was significantly related 
to patient satisfaction, and as far as clinical factors are 
concerned, nearly all except for immunosuppressive 
therapy were associated with patient satisfaction 
(Tables 3 and 4). Multiple logistic regression analysis 
showed that education (p = 0.04), monthly income 
(p =  0.01), SLEDAI score (p = 0.031), DMARDs therapy 
(p = 0.029), ISs therapy (p = 0.01), and CSs therapy 
(p = 0.01) predicted patient dissatisfaction with current 
clinical management and status monitoring (Table 5).
 Discussion
The main finding of our study is the low rate 
of patient satisfaction (16.4%). This finding is very 
similar to that of Chinese colleagues, who reported 
on 32.38% satisfaction rate of SLE patients, which 
was influenced by the defects in patients’ education 
on health-care system [20]. Clinical manifestations of 
SLE and quality of life also significantly correlated with 
patient satisfaction [21]. Prescription of certain types of 
medications like CSs plays a role in reduced satisfaction 
of SLE patients [22]. Besides, lack of social support and 
low-quality medical services can undermine the trust of 
SLE patients in care provided [23]. There are several 
possible explanations for low patient satisfaction that 
needs to be considered in detail.
In the study, we found that variables level of 
education (OR = 1.251; 95% CI: 1.005–2.453), monthly 
income (OR = 2.41; 95% CI: 1.543–6.419), SLEDAI 
score (OR = 1.511; 95% CI: 1.218-3.241), DMARDs 
therapy (OR = 1.619; 95% CI: 1.013–1.986), ISs therapy 
(OR = 1.321; 95% CI: 1.014–3.494), and CSs therapy 
(OR = 2.163; 95% CI: 1.300–3.045) were significantly 
associated with patient dissatisfaction.
A recent systematic review [24] investigated 
different factors associated with patient satisfaction and 
identified quality indicators of health-care services as the 
most powerful determinants. According to this review, 
there are nine determinants of satisfaction with existing 
health-care services, some of which are of greater 
importance than others. In particular, both continuity 
of care and outcome of care have significantly positive 
effects on overall patient satisfaction. These could be 
considered from two perspectives: Provider-related and 
patient-related. While patients tend to assess the impact 
of care in terms of their daily life activities, doctors tend 
to rely on clinical indicators.
Table 2: Clinical findings in SLE patients (n = 67)
Symptoms and signs f %
Musculoskeletal symptoms 64 95.5
Fatigue 59 88.1
Neurological symptoms 36 53.7
Gastrointestinal symptoms 33 49.3
Cardiovascular symptoms 30 44.8
Mucocutaneous symptoms 29 43.3
Raynaud’s phenomenon 28 41.8
Fever 26 38.8
Skin rash 19 28.4
Respiratory symptoms 15 22.4
Morning stiffness 13 19.4
Nodules 12 17.9
Ulcers 11 16.4
Infection 11 16.4
Depression/anxiety 9 13.4
Genitourinary symptoms 7 10.4
Significant infection 5 7.5
Thrombosis 3 4.5
Seizures 1 1.5
SLE: Systemic lupus erythematosus.
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In our study, almost all patients had 
musculoskeletal symptoms – one of the most influential 
predictors of poor ability to perform daily life activities. 
Arthritis and myositis are two common manifestations of 
SLE and are both associated with significant pain and 
physical disability [25]. Although typical SLE affects small 
joints, larger joints may be also involved, making the 
daily routine tasks of the patients difficult [26]. Arthralgia 
and myalgia – other common manifestations of SLE – 
contribute to decreased physical functioning and provoke 
psychological distress [27]. Besides, fatigue is one of 
the main findings in SLE and it was observed in almost 
90% of our study population. Fatigue is not necessarily 
related to disease activity but is rather correlated with 
Table 4: Patient satisfaction in relation to clinical characteristics (n = 67)
Characteristic Overall satisfaction Test of difference
Very dissatisfied Dissatisfied Somewhat dissatisfied Somewhat satisfied Satisfied Very satisfied χ2 p-value
n % 95% CI n % 95% CI n % 95% CI n % 95% CI n % 95% 
CI
n % 95% 
CI
Duration of follow-up
≤1 year 2 9.1 2.53–
27.81
1 4.3 0.80–
20.99
7 63.6 35.38–
84.84
2 18.2 5.14–4.77 0 0 - 0 0 - 19.685 0.000
>1 year 20 90.9 72.19–
97.47
22 95.7 79.01–
99.23
4 36.4 15.16–
64.62
9 81.8 52.30–
94.86
0 0 - 0 0 -
Presence of disability
Yes 10 45.5 26.92–
65.34
10 43.5 25.64–
63.19
2 18.2 5.14–
4.77
10 90.9 62.27–
98.38
0 0 - 0 0 - 12.282 0.006
No 12 54.5 34.66–
73.08
13 56.5 36.81–
74.36
9 81.8 52.30–
94.86
1 9.1 1.62–
37.73
0 0 - 0 0 -
SLICC/ACR score
=0 0 0 - 0 0 - 0 0 - 0 0 - 0 0 - 0 0 - - -
≥1 22 100.0 - 23 100.0 - 11 100.0 - 11 100.0 - 0 0 - 0 0 -
SLEDAI score
<4 5 22.7 10.12–
43.44
6 26.1 12.55–
46.47
2 18.2 5.14–
4.77
9 81.8 52.30–
94.86
0 0 - 0 0 - 14.532 0.002
≥4 17 77.3 56.56–
89.88
17 73.9 53.53–
87.45
9 81.8 52.30–
94.86
2 18.2 5.14–4.77 0 0 - 0 0 -
DMARDs therapy
Yes 0 0.0 - 0 0.0 - 0 0.0 - 2 18.2 5.14–4.77 0 0 - 0 0 - 10.495 0.015
No 22 100.0 - 23 100.0 - 11 100.0 - 9 81.8 52.30–
94.86
0 0 - 0 0 -
ISs therapy
Yes 18 81.8 61.49–
92.69
21 91.3 7.32–
97.58
11 100.0 - 10 90.9 62.27–
98.38
0 0 - 0 0 - 2.782 0.426
No 4 18.2 7.31–
38.51
2 8.7 2.40–
2.68
0 0.0 - 1 9.1 1.62–
37.73
0 0 - 0 0 -
CSs therapy
Yes 1 4.5 0.80–2.18 2 8.7 2.40–
2.68
0 0.0 - 8 72.7 43.44–
90.26
0 0 - 0 0 - 30.837 0.000
No 21 95.5 78.20–
99.19
21 91.3 7.32–
97.58
11 100.0 - 3 27.3 9.74–
56.56
0 0 - 0 0 -
OR: Odds ratio, CI: Confidence interval, SLICC/ACR: Systemic Lupus International Collaborating Clinics American College of Rheumatology, SLEDAI: Systemic lupus erythematosus disease activity index, DMARD: Disease-
modifying antirheumatic drugs.
Table 3: Patient satisfaction in relation to sociodemographic characteristics (n = 67)
Characteristic Overall satisfaction Test of difference
Very dissatisfied Dissatisfied Somewhat dissatisfied Somewhat satisfied Satisfied Very satisfied χ2 p-value
n % 95% CI n % 95% CI n % 95% CI n % 95% CI n % 95% CI n % 95% CI
Age, years
>20 0 0 - 2 8.70 2.42–
26.8
1 9.09 1.62–
37.73
1 9.09 1.62–
37.73
0 0 - 0 0 - 12.595 0.634
20–29 7 31.82 16.36–52.68 3 13.04 4.54–
32.12
0 0.00 - 2 18.18 5.14–
47.70
0 0 - 0 0 -
30–39 4 18.18 7.31–38.51 8 34.78 18.81–
55.11
3 27.27 9.74–
56.56
3 27.27 9.74–
56.56
0 0 - 0 0 -
40–49 7 31.82 16.36–52.68 5 21.74 9.66–
41.90
5 45.45 21.27–
71.99
2 18.18 5.14–
47.70
0 0 - 0 0 -
50–59 3 13.64 4.75–33.34 5 21.74 9.66–
41.90
2 18.18 5.14–
47.70
3 27.27 9.74–
56.56
0 0 - 0 0 -
>60 1 4.55 0.81–21.80 0 0.00 - 0 0.00 - 0 0.00 - 0 0 - 0 0 -
Gender
Female 22 100.00 - 22 95.65 79.01–
99.23
11 100.00 - 11 100.00 - 0 0 - 0 0 - 1.942 0.585
Male 0 0.00 - 1 4.35 0.77–
20.99
0 0.00 - 0 0.00 - 0 0 - 0 0 -
Education
Unfinished 
secondary
9 40.91 23.26–61.27 0 0.00 - 0 0.00 - 0 0.00 - 0 0 - 0 0 - 47.639 0.000
Secondary 3 13.64 4.75–33.34 17 73.91 53.53–
87.45
5 45.45 21.27-
71.99
0 0.00 - 0 0 - 0 0 -
Secondary 
vocational
6 27.27 13.15–48.15 1 4.35 0.77–
20.99
3 27.27 9.74–
56.56
8 72.73 43.44–
90.26
0 0 - 0 0 -
Higher 4 18.18 7.31–38.51 5 21.74 9.66–
41.90
3 27.27 9.74–
56.56
3 27.27 9.74–
56.56
0 0 - 0 0 -
Monthly income
≤83,000 
KZT*
22 100.00 - 19 82.61 62.86–
93.02
9 81.82 52.30–
94.86
3 27.27 9.74–
56.56
0 0 - 0 0 - 23.910 0.000
More than 
83,000 
KZT*
0 0.00 - 4 17.39 6.98–
37.14
2 18.18 5.14–
47.70
8 72.73 43.44–
90.26
0 0 - 0 0 -
*KZT=Kazakh Tenge. OR: Odds ratio, CI: Confidence interval.
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other factors such as the presence of mental distress and 
pain syndrome [28]. Since musculoskeletal symptoms 
and fatigue prevailed in our patients, these could be one 
of the possible explanations for the high dissatisfaction 
rate. Possibly a high fatigue prevalence in Kazakhstani 
SLE patients could be also associated with geographical 
features of the country that characterized by Vitamin D 
deficiency [29].
In addition, neurological symptoms and 
presence of depression or anxiety are correlated with 
decreased psychological functioning and also affect 
patient satisfaction. Seizures and cerebrovascular 
disease, such as permanent or transient cerebral 
ischemic episodes, are considered the most common 
neurological manifestations of SLE [30]. Although 
seizures were observed in only one patient in our 
study, more than half of all patients presented with 
some neurological symptoms. Depression is one of 
the commonest psychiatric manifestations of SLE, 
with prevalence rates ranging from 17 to 75% [31]. 
Despite the fact that in our study, only a few patients 
had symptoms of depression or anxiety, these numbers 
are likely to be underestimated as both depression and 
anxiety are stigmatized in Kazakhstan [32] and doctor 
who is not psychiatrists has little ability to recognize and 
properly manage them. Depression and anxiety may 
have also contributed to our patients’ dissatisfaction.
Albeit there was a relatively small proportion 
of patients presenting with genitourinary symptoms 
(10.4%), nephritis is a frequent complication of SLE 
and substantially contributes to lethality [33]. In general, 
chronic kidney disease tends to be underestimated by 
health-care providers in Kazakhstan. This situation 
is very similar to the one observed in the Russian 
Federation, which experiences acute insufficient 
staffing in nephrology services along with the insufficient 
provision of renal replacement therapy [34]. Thus, there 
is a need to introduce international clinical practice 
guidelines on diagnostic, therapeutic, and preventive 
approaches for SLE patients presenting with nephritis 
and to increase awareness among both medical 
professionals and patients on associated health risks.
Availability of health care, including effective 
and timely therapy, is another determinant of patient 
satisfaction and is inter-related with treatment 
outcomes [24]. DMARDs are a new approach to 
managing disease activity and Belimumab is the only 
biological agent currently registered in Kazakhstan for 
SLE treatment. In this study, only two patients were 
on Belimumab and both were somewhat satisfied with 
the current clinical management. Logistic regression 
analysis showed that non-provision of Belimumab is 
also a predictor of patient dissatisfaction (p = 0.029).
Since DMARDs therapy can reduce SLE 
activity and flares, its unavailability is associated with the 
increased use of other anti-SLE agents such as CSs and 
ISs. According to the recommendations of the European 
League Against Rheumatism, ISs should be considered 
in non-responsive SLE patients, or in those patients 
who require CSs above the doses recommended for 
chronic use [35]. Although CSc and ISs have many 
known side effects, they can effectively control SLE 
activity and in our study non-provision of CSs or ISs 
therapy was found to be a statistically significant risk 
factor for patients’ dissatisfaction with current disease 
management (p = 0.001). This was also associated with 
SLE activity based on SLEDAI score, with a cutoff value 
of 4: Those patients who presented with active disease 
had a higher chance to be dissatisfied with current SLE 
management as compared to those who presented with 
inactive disease (SLEDAI score < 4).
In general, patient-related characteristics such 
as age, gender, level of education, monthly income, 
marital status, ethnicity, and length of follow-up are 
considered less powerful determinants of patient 
satisfaction [24]. Although in our study, we failed to 
establish associations between patient dissatisfaction 
and age, gender or duration of follow-up, level of 
education, and monthly income were found to be strong 
predictors of discontent. Such,  patients with secondary 
or unfinished secondary education had higher odds 
(OR = 1.25) of being dissatisfied with the quality of 
care provided as compared to patients with higher or 
secondary vocational education. This finding helps to 
conclude that the level of patient education has a direct 
relationship with patient satisfaction. In addition, patients 
with monthly income below the country’s average had a 
2.4 times higher chance of being dissatisfied with SLE 
management compared to their wealthier counterparts.
Table 5: Logistic regression analysis of predictors (risk factors) 
for patient dissatisfaction with current clinical management 
and status monitoring (n = 67)
Risk factors Outcome variable
Patient dissatisfaction
OR (95% CI) p-value
Education
Secondary vocational and higher Reference -
Secondary and unfinished secondary 1.251 (1.005–2.453) 0.040
Age
<40 years Reference -
≥40 years 0.831 (0.215–4.589) 0.831
Gender
Female Reference -
Male 1.213 (0.637–3.322) 0.944
Monthly income
≤83,000 KZT* 2.41 (1.543–6.419) 0.010
More than 83,000 KZT* Reference -
Duration of follow-up
≤1 year Reference -
>1 year 0.94 (0.116–1.118) 0.999
SLICC/ACR score
=0 Reference -
≥1 1.256 (0.426–1.215) 0.742
SLEDAI score
<4 Reference -
≥4 1.511 (1.218–3.241) 0.031
DMARDs therapy
Yes Reference -
No 1.619 (1.013–1.986) 0.029
ISs therapy
Yes Reference -
No 1.321 (1.014–3.494) 0.001
CSs therapy
Yes Reference -
No 2.163 (1.300–3.045) 0.001
*KZT=Kazakh Tenge. OR: Odds ratio, CI: Confidence interval, SLICC/ACR: Systemic Lupus International 
Collaborating Clinics American College of Rheumatology, SLEDAI: Systemic lupus erythematosus disease 
activity index, DMARD: Disease-modifying antirheumatic drugs.
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Implications for the practice of health-care 
managers
Since there is a lack of Kazakhstani studies on 
patient satisfaction with the quality of medical care, the 
results of this research could be useful for health-care 
managers as they enable a better understanding of the 
factors affecting the satisfaction of SLE patients and 
give insights on what needs to be done to improve it.
Kazakhstan Republic experienced rapid 
economic growth over the past decades of years 
and is now considered to be one of the emerging 
economies [36]. Being led by extensive oil production, the 
country’s government took measures to equip the health-
care facilities with the latest diagnostic and treatment 
tools to enable adequate quality of health-care provided 
to the country population [12]. Furthermore, health-care 
managers strived to ensure that medical professionals 
meet requirements set by the Ministry of Health that 
dictates competences and qualifications of health-care 
providers. However, the issue of patient satisfaction is 
often overlooked by health-care managers in their attempt 
to upgrade the quality of health services [13].
Still, the degree of patient satisfaction could 
serve as one of the key performance indicators for health-
care services as it has a direct impact on the status of 
any health-care facility. In general, patient satisfaction 
signifies a facility’s success on the basis of satisfactory 
patient feedback [37]. Moreover, it can be one of the key 
indicators for adjudicating health outcomes of individual 
patients. Good patient satisfaction is a preferred outcome 
of any medical care and is an important aspect of patient’s 
health status [38]. As patient satisfaction is a valuable 
measurement of the quality of medical care, this research 
contributes to enhancement of the quality of health-care 
services provided to SLE patients in Kazakhstan.
Strengths and limitations
This study has several strengths and limitations. 
The major limitations come from its cross-sectional 
design and from the fact that it is being a single-city 
study. However, there are several strengths and the 
main one is that this is the first Kazakhstani study to 
report about the experiences of SLE patients within the 
local health-care system, which may facilitate doctor-
patient discussions on what steps need to be taken to 
improve the quality of medical services provided.
 Conclusion
The results of this study show the low 
satisfaction of SLE patients with medical services 
provided in Semey and identify the key determinants 
of patient dissatisfaction. The type of therapy provided 
along with SLE activity, level of education, and patient’s 
monthly income appeared to be the key drivers of 
dissatisfaction. The management of patients with SLE 
as well with other chronic diseases in Kazakhstan 
remains provider-centered and little emphasis is placed 
on the recognition of patient’s perceptions and views. 
Consideration of patients’ views and experiences is 
essential if a program aiming to improve the quality of 
care of SLE is envisaged. In addition, the findings of 
our study may facilitate the start of a dialog with the 
health-care authorities on the current status of SLE 
management in Kazakhstan and may help to achieve 
better clinical outcomes in the future.
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